Cardiology transaction activity remains strong, but the underlying investment strategy has evolved significantly over the last several years. Historically, many cardiovascular procedures were confined to the hospital setting because Medicare reimbursement and regulatory limitations restricted migration to outpatient settings. Today, that dynamic is changing rapidly. Expanded reimbursement eligibility, advancements in procedural technology, and growing confidence in ambulatory cardiovascular care are reshaping how investors, health systems, and physician groups approach cardiology outpatient strategy. 

The most important shift in the market is the migration of cardiovascular procedures from hospitals to ambulatory surgery centers (ASCs). Industry leaders increasingly expect a substantial portion, some say up to 80%, of cardiology services currently performed in hospitals to transition to outpatient environments by 2030. This transition accelerated following Medicare reimbursement changes that expanded the number of cardiovascular procedures eligible for ASC payment, including coronary interventions, and, in January 2026, new electrophysiology-related procedures. 

As reimbursement expands, new capital continues to enter the market. Health systems, private equity–backed platforms, and strategic operators are all competing to establish or expand outpatient cardiovascular footprints.

Large strategic operators and private equity–backed organizations increasingly view cardiology as one of the largest remaining, untapped outpatient growth opportunities in healthcare. 

What makes the opportunity especially attractive is that cardiology procedural volumes are largely incremental to existing ASC operations. Unlike specialties such as gastroenterology, where outpatient infrastructure is already mature, cardiology procedures have historically remained hospital-based. As procedures migrate to ASCs, operators are effectively adding entirely new procedural volume to outpatient settings rather than merely redistributing existing ASC activity.

At the same time, demographic trends continue to support long-term cardiovascular demand. Aging Baby Boomers are driving up healthcare utilization, creating sustained procedural growth even as care settings shift. For many health systems, the strategic objective is no longer simply protecting hospital procedural volume; it is to participate in simultaneous growth in both inpatient and outpatient cardiovascular care. 

The Decline of the OBL–ASC Hybrid Model

For several years, many cardiology groups operated hybrid office-based laboratory (OBL) and ASC models within the same facility footprint. These arrangements often allowed groups to maximize reimbursement opportunities depending on procedural eligibility and payer dynamics. However, industry leaders increasingly believe this model may become less common over time. 

The primary reason is reimbursement convergence. Historically, some procedures generated more favorable economics in the OBL setting. As ASC reimbursement has expanded and, in some cases, exceeded OBL reimbursement, the operational complexity of maintaining dual structures has become more difficult to justify. 

These hybrid arrangements also create meaningful valuation and transaction complexity. Buyers must assess shared staffing models, space allocation, equipment utilization, reimbursement optimization strategies, and ownership structures across multiple legal entities. From a transaction perspective, it’s critical to determine precisely which assets are being acquired—is the transaction limited to just the ASC, or does it also include the OBL? How those assets generate cash flow can materially influence valuation conclusions. 

As more cardiovascular procedures become ASC-eligible, many operators may favor fully integrated ASC models that simplify governance, reimbursement administration, and operational management. 

Scaling Cardiology Remains Operationally Challenging

Despite significant investor interest, cardiology consolidation remains more operationally complex than many other physician specialties. Unlike gastroenterology, ophthalmology, or orthopedics—where large independent physician bases facilitate rapid platform expansion—most cardiologists are already employed by hospitals or health systems. This creates additional friction for organizations attempting to hire to scale independent cardiovascular platforms. 

In addition, cardiology outpatient infrastructure remains relatively immature compared to more established ASC specialties. Operators are still navigating payer contracting challenges, evolving reimbursement structures, optimizing procedural workflows, and aligning with physicians. 

Consumer perception also remains an important variable. While outpatient orthopedic or gastrointestinal procedures are now widely accepted, cardiovascular interventions represent a newer frontier in the ASC environment, potentially causing patient concern about emergency preparedness and hospital proximity. As a result, some organizations are prioritizing ASC development models that are physically connected to, or closely aligned with, hospitals to  support clinical integration, quality oversight, and connected coordinated cardiovascular care. 

Operational execution is therefore becoming increasingly important in distinguishing successful platforms from struggling ones. Investors are underwriting not only procedural growth potential, but also physician alignment, market density, reimbursement sustainability, facility strategy, and long-term operational scalability. 

A More Disciplined Future for Cardiology Platforms

Cardiology is no longer a simple, physician practice roll-up strategy. Increasingly, success depends on disciplined market selection, thoughtful site-of-care planning, and operational sophistication. 

Organizations that move early to evaluate state regulations, procedural migration opportunities, physician alignment structures, and outpatient facility needs may establish significant competitive advantages over the next several years. However, local market dynamics, need for innovative physician alignment with existing physician employers, and state regulatory frameworks will likely create uneven adoption across geographies, particularly where legacy laws continue to restrict outpatient cardiovascular care models. 

The cardiology ASC market remains in an early stage of development compared to other outpatient specialties, but momentum is clearly accelerating. For physician groups, health systems, and investors alike, the next phase of growth will likely favor organizations that can pair capital with operational execution, regulatory awareness, and a clearly defined outpatient cardiovascular strategy. 

Navigating growth opportunities, transactions, and operational complexity requires strategic precision. Connect with VMG Health to evaluate your cardiovascular strategy and identify opportunities for sustainable growth.